EAEU Regulatory Requirements and CTD Dossier Preparation for Marketing Authorization of Cerebroprotein Hydrolysate for Injection: A Review

  • Unique Paper ID: 211119
  • Volume: 13
  • Issue: 6
  • PageNo: 3827-3842
  • Abstract:
  • Cerebroprotein Hydrolysate for Injection is a complex biological-derived medicinal product for which comprehensive documentation of quality, safety, and efficacy is essential for regulatory evaluation. Marketing authorization within the Eurasian Economic Union (EAEU) requires compliance with harmonized regulatory requirements and submission of a structured Common Technical Document (CTD) dossier. This review aims to provide an overview of the EAEU regulatory framework applicable to Cerebroprotein Hydrolysate for Injection and to discuss the major requirements for preparation and submission of a CTD dossier for marketing authorization. The EAEU has established common principles and rules for the registration and circulation of medicinal products among its Member States. The regulatory framework includes requirements for registration, expert assessment, quality documentation, safety and efficacy evaluation, labeling, and post-marketing obligations. Decision No. 78 of the Council of the Eurasian Economic Commission provides the principal procedural framework for registration and examination of medicinal products. The CTD dossier should present administrative information and comprehensive scientific evidence in a standardized format covering quality, non-clinical, and clinical documentation. Particular emphasis is required on product-specific pharmaceutical development, manufacturing processes, characterization and control of the active substance and finished product, analytical procedures, specifications, stability data, and relevant safety and efficacy evidence. Appropriate consistency and traceability of information across CTD modules are essential for regulatory assessment. Major challenges include interpretation and implementation of evolving EAEU requirements, generation of adequate product-specific data for complex biological-derived preparations, ensuring consistency of technical information across the dossier, compliance with administrative and labeling requirements, and responding appropriately to questions raised during regulatory assessment. Continuous monitoring of amendments to EAEU regulations and guidelines is therefore important for maintaining submission compliance. A complete, scientifically justified, and EAEU-compliant CTD dossier provides the essential evidence base for regulatory assessment of Cerebroprotein Hydrolysate for Injection. Effective regulatory planning, product-specific scientific documentation, rigorous quality data, and adherence to current EAEU requirements can facilitate a transparent assessment of the product's quality, safety, and efficacy and support the marketing authorization process.

Copyright & License

Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{211119,
        author = {Nishant Yadav and Ritu},
        title = {EAEU Regulatory Requirements and CTD Dossier Preparation for Marketing Authorization of Cerebroprotein Hydrolysate for Injection: A Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {6},
        pages = {3827-3842},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=211119},
        abstract = {Cerebroprotein Hydrolysate for Injection is a complex biological-derived medicinal product for which comprehensive documentation of quality, safety, and efficacy is essential for regulatory evaluation. Marketing authorization within the Eurasian Economic Union (EAEU) requires compliance with harmonized regulatory requirements and submission of a structured Common Technical Document (CTD) dossier. This review aims to provide an overview of the EAEU regulatory framework applicable to Cerebroprotein Hydrolysate for Injection and to discuss the major requirements for preparation and submission of a CTD dossier for marketing authorization. The EAEU has established common principles and rules for the registration and circulation of medicinal products among its Member States. The regulatory framework includes requirements for registration, expert assessment, quality documentation, safety and efficacy evaluation, labeling, and post-marketing obligations. Decision No. 78 of the Council of the Eurasian Economic Commission provides the principal procedural framework for registration and examination of medicinal products. The CTD dossier should present administrative information and comprehensive scientific evidence in a standardized format covering quality, non-clinical, and clinical documentation. Particular emphasis is required on product-specific pharmaceutical development, manufacturing processes, characterization and control of the active substance and finished product, analytical procedures, specifications, stability data, and relevant safety and efficacy evidence. Appropriate consistency and traceability of information across CTD modules are essential for regulatory assessment. Major challenges include interpretation and implementation of evolving EAEU requirements, generation of adequate product-specific data for complex biological-derived preparations, ensuring consistency of technical information across the dossier, compliance with administrative and labeling requirements, and responding appropriately to questions raised during regulatory assessment. Continuous monitoring of amendments to EAEU regulations and guidelines is therefore important for maintaining submission compliance. A complete, scientifically justified, and EAEU-compliant CTD dossier provides the essential evidence base for regulatory assessment of Cerebroprotein Hydrolysate for Injection. Effective regulatory planning, product-specific scientific documentation, rigorous quality data, and adherence to current EAEU requirements can facilitate a transparent assessment of the product's quality, safety, and efficacy and support the marketing authorization process.},
        keywords = {Cerebroprotein Hydrolysate; EAEU; Common Technical Document; CTD; Marketing Authorization; Regulatory Affairs.},
        month = {November},
        }

Cite This Article

Yadav, N., & Ritu, (2026). EAEU Regulatory Requirements and CTD Dossier Preparation for Marketing Authorization of Cerebroprotein Hydrolysate for Injection: A Review. International Journal of Innovative Research in Technology (IJIRT), 13(6), 3827–3842.

Related Articles